Phenomenome Discoveries Inc. (PDI) is a human health research company that uses its patented metabolomic biomarker discovery platform and patented informatic research tools to discover novel metabolite biomarkers. PDI has small molecule serum biomarker discovery programs in cancer and neurodegenerative disease, and has validated and filed patents on diagnostic biomarkers in multiple human health disorders.
In 2012, PDI launched COLOGIC, together with its Canadian market commercialization partner, CML HealthCare Inc. COLOGIC is a simple blood test that screens for colorectal cancer. This is the first step in the global commercialization strategy for this test, and others like it in PDI's research and development pipeline.
PDI is uniquely positioned within the market, offering expertise in discovery and subsequent elucidation of the biological relevance of biomarkers as well as the development of highly efficient targeted assays for validated, relevant biomarkers. PDI is located in Saskatoon, Canada, and was founded in 2000.
Since our founding in 2000, researchers at Phenomenome Discoveries Inc. have been using our patented technology to examine biological samples in the search for small chemicals called metabolites that are indicators of health state and health risk. Looking at all the metabolites in a sample at once is called metabolomics, and Phenomenome has spent seven years developing metabolomics methods and tools for use in our research.
Our metabolomics tools allow us to compare samples, such as blood, from people with a health condition to samples from people with optimal health. Our goal is to learn more about human health and the biochemical basis of disease, so that we can help identify health risks before disease develops.
Our internal research division includes teams focusing on discovery research, analytical method research, and informatic tool development. We also have research programs with collaborators around the world, and offer contract research solutions for commercial customers.